Breast Tumors Shed Their HER2 Target in More Than Half of Cases After Drug Therapy
A new MD Anderson study finds that 57 percent of residual breast tumors lose HER2 overexpression after HER2-targeted neoadjuvant therapy, ...
A new MD Anderson study finds that 57 percent of residual breast tumors lose HER2 overexpression after HER2-targeted neoadjuvant therapy, ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine